|
Total patients
|
HPD (n = 26)
|
SD/PR/CR (n = 129)
|
P value
|
|---|
|
Age (year)
|
58.96 ± 10.2
|
65.19 ± 9.1
|
0.002
|
|
Gender, Female: Male
|
3:23
|
35:94
|
0.092
|
|
Smoking history (pack/y)
|
29.3 ± 19.6
|
24.41 ± 21.6
|
0.284
|
|
< 20
|
5
|
51
|
0.049
|
|
≥ 20
|
21
|
78
| |
|
Histologic subtype
| | |
0.061
|
|
Adenocarcinoma
|
14
|
93
| |
|
Squamous cell carcinoma
|
11
|
34
| |
|
Others
|
1
|
2
| |
|
Oncogenic driver mutations
| | | |
|
Yes: No
|
8:18
|
16:113
|
0.018
|
|
EGFR mutation
|
5
|
7
| |
|
ALK, ROS1, and others
|
3
|
9
| |
|
Number of metastatic sites
| | |
0.005
|
|
< 3
|
17
|
113
| |
|
≥ 3
|
9
|
16
| |
|
Prior treatment lines before ICBs
| | |
0.139
|
|
< 3
|
21
|
117
| |
|
≥ 3
|
5
|
12
| |
- Values are presented as mean ± standard deviation, ratio, or number
- aNon-evaluable group and non-HPD PD group were excluded
- ALK Anaplastic lymphoma kinase, EGFR epidermal growth factor receptor, HPD hyperprogressive disease, Non-HPD PD non-HPD progressive disease, OS overall survival, PR/CR partial/complete response, SD stable disease
